{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:53:01Z","timestamp":1789386781507,"version":"build-2803163510"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1097\/rlu.0b013e31823926c9","type":"journal-article","created":{"date-parts":[[2012,4,4]],"date-time":"2012-04-04T10:14:21Z","timestamp":1333534461000},"page":"460-466","source":"Crossref","is-referenced-by-count":28,"title":["18F-FDG Retention Index and Biologic Prognostic Parameters in Breast Cancer"],"prefix":"10.1097","volume":"37","author":[{"given":"Ana Mar\u00eda","family":"Garc\u00eda Vicente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel Soriano","family":"Castrej\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Relea Calatayud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azahara Palomar","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Alberto","family":"Le\u00f3n Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio Chac\u00f3n","family":"L\u00f3pez-Mu\u00f1iz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"del Mar Mu\u00f1oz S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Cordero Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward Mitsuro","family":"Becerra Nakayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210204","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00000658-199408000-00003","article-title":"Current management of carcinoma of the breast.","volume":"2","author":"Eberlein","year":"1994","journal-title":"Ann Surg"},{"key":"R2-6-20210204","first-page":"4","article-title":". Prospective evaluation of 18FFDG positron emission tomography (PET) in the presurgical staging of the axilla in breast cancer: comparison between PET and postoperative pathology.","volume":"39","author":"Crippa","year":"1998","journal-title":"J Nucl Med"},{"key":"R3-6-20210204","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.crad.2008.03.014","article-title":". Dual time point FDG-PETCT imaging. Potential tool for diagnosis of breast cancer.","volume":"63","author":"Zytoon","year":"2008","journal-title":"Clin Radiol"},{"key":"R4-6-20210204","first-page":"1440","article-title":". Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes.","volume":"47","author":"Mavi","year":"2006","journal-title":"J Nucl Med"},{"key":"R5-6-20210204","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ejrad.2008.01.045","article-title":". Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PETCT.","volume":"70","author":"Zytoon","year":"2009","journal-title":"Eur J Radiol"},{"key":"R6-6-20210204","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/bjs.6459","article-title":". Association between 18F fluorodeoxyglucose uptake and prognostic parameters in breast cancer.","volume":"96","author":"Gil-Rendo","year":"2009","journal-title":"Br J Surg"},{"key":"R7-6-20210204","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00259-002-0880-8","article-title":". FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters.","volume":"29","author":"Buck","year":"2002","journal-title":"Eur J Nucl Med"},{"key":"R8-6-20210204","first-page":"9","article-title":". Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.","volume":"42","author":"Avril","year":"2001","journal-title":"J Nucl Med"},{"key":"R9-6-20210204","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/cncr.23226","article-title":". Comparison of triple-negative and estrogen receptorpositive progesterone receptor positiveHER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucosepositron emission tomography imaging parameters. A potentially useful method for disease characterization.","volume":"112","author":"Basu","year":"2008","journal-title":"Cancer"},{"key":"R10-6-20210204","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2325\/jbcs.14.260","article-title":". The relationship between FDG uptake in PET scans and biological behavior in breast cancer.","volume":"14","author":"Shimoda","year":"2007","journal-title":"Breast Cancer"},{"key":"R11-6-20210204","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0212-6982(09)70706-2","article-title":"Tomografia por emision de positrones de cuerpo completo (PETTAC) con 18F-fluorodesoxiglucosa.","volume":"28","author":"Garcia Garzon","year":"2009","journal-title":"Rev Esp Med Nucl"},{"key":"R13-6-20210204","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s10147-010-0120-3","article-title":". Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors.","volume":"15","author":"Heudel","year":"2010","journal-title":"Int J Clin Oncol"},{"key":"R14-6-20210204","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00432-003-0536-5","article-title":". Preoperative evaluation of prognosis in breast cancer patients by (18)F2-deoxy-2-fluoro-D-glucose-positron emission tomography.","volume":"130","author":"Inoue","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"R15-6-20210204","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12282-008-0065-9","article-title":"Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy.","volume":"16","author":"Uematsu","year":"2009","journal-title":"Breast Cancer"},{"key":"R16-6-20210204","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00259-010-1640-9","article-title":". Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.","volume":"38","author":"Groheux","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R18-6-20210204","first-page":"1766","article-title":". Positron tomographic assessment of estrogen receptors in breast cancer: a comparison with FDG-PET and in vitro receptor assays.","volume":"36","author":"Dehdashti","year":"1995","journal-title":"J Nucl Med"},{"key":"R19-6-20210204","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s002590050319","article-title":". Association between F-18 fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation.","volume":"25","author":"Crippa","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"R20-6-20210204","first-page":"1412","article-title":". Dual time point F-18-FDG PET imaging for differentiating malignant from inflammatory processes.","volume":"42","author":"Zhuang","year":"2001","journal-title":"J Nucl Med"},{"key":"R21-6-20210204","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s002590100537","article-title":". Advantage of delayed whole-body FDG-PET imaging for tumour detection.","volume":"28","author":"Kubota","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"R22-6-20210204","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/00006231-200311000-00002","article-title":"Narrow time-window dual-point F-18-FDG PET for the diagnosis of thoracic malignancy.","volume":"24","author":"Conrad","year":"2003","journal-title":"Nucl Med Commun"},{"key":"R23-6-20210204","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1200\/JCO.2004.04.148","article-title":". Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.","volume":"22","author":"Wahl","year":"2004","journal-title":"J Clin Oncol"},{"key":"R24-6-20210204","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/annonc\/mdl425","article-title":". A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.","volume":"18","author":"Veronesi","year":"2007","journal-title":"Ann Oncol"},{"key":"R25-6-20210204","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00259-009-1145-6","article-title":". Diagnostic value of full-dose FDG-PETCT for axillary lymph node staging in breast cancer patients.","volume":"36","author":"Heusner","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003072-201205000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:34:51Z","timestamp":1786048491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003072-201205000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0b013e31823926c9","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}